Abstract Spinocerebellar ataxia type 2 (SCA2) is caused by triple nucleotide repeat (CAG) expansion in the coding region of the ATAXN2 gene on chromosome 12, which produces an elongated, toxic polyglutamine tract, leading to Purkinje cell loss. There is currently no effective therapy. One of the main obstacles that hampers therapeutic development is lack of an ideal disease model. In this study, we have generated and characterized SCA2-induced pluripotent stem (iPS) cell lines as an in vitro cell model. Dermal fibroblasts (FBs) were harvested from primary cultures of skin explants obtained from a SCA2 subject and a healthy subject. For reprogramming, hOct4, hSox2, hKlf4, and hcMyc were transduced to passage-3 FBs by retroviral infection. Both SCA2 iPS and control iPS cells were successfully generated and showed typical stem cell growth patterns with normal karyotype. All iPS cell lines expressed stem cell markers and differentiated in vitro into cells from three embryonic germ layers. Upon in vitro neural differentiation, SCA2 iPS cells showed abnormality in neural rosette formation but successfully differentiated into neural stem cells (NSCs) and subsequent neural cells. SCA2 and normal FBs showed a comparable level of ataxin-2 expression; whereas SCA2 NSCs showed less ataxin-2 expression than normal NSCs and SCA2 FBs. Within the neural lineage, neurons had the most abundant expression of ataxin-2. Time-lapsed neural growth assay indicated terminally differentiated SCA2 neural cells were short-lived compared with control neural cells. The expanded CAG repeats of SCA2 were stable throughout reprogramming and neural differentiation. In conclusion, we have established the first disease-specific human SCA2 iPS cell line. These mutant iPS cells have the potential for neural differentiation. These differentiated neural cells harboring mutations are invaluable for the study of SCA2 pathogenesis and therapeutic drug development.
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In conclusion, we have established the first disease-specific human SCA2 iPS cell line. These mutant iPS cells have theIntroduction Spinocerebellar ataxia type 2 (SCA2; OMIM No. 183090) is caused by a triple nucleotide (CAG) repeat expansion in the coding region of the ATAXN2 gene on chromosome 12. Worldwide, it is the second most common SCA after SCA3. Clinically, SCA2 belongs to a group of SCAs known as autosomal-dominant cerebellar ataxia type 1 (ADCA-1), in which cerebellar ataxia (the core phenotype) is associated with extracerebellar neurological abnormalities. Like other disorders of the ADCA-1, the extracerebellar manifestations of SCA2 may include parkinsonism, progressive cognitive impairments, palatal and generalized myoclonus, optic atrophy, distal sensory loss, and adult-onset spinomuscular atrophy (Eto et al. 1990; Auburger 2012) . However, progressively slow saccadic eye movements that start at an early stage of the disease and areflexia, which is often confined to the upper extremities in the beginning stage, distinguish SCA2 from other SCAs. Brains from SCA2 patients showed cytoplasmic (but not nuclear) microaggregates containing expanded polyglutamines with loss of cerebellar Purkinje cell dendritic arbor and eventual cell loss . The expansion of CAG repeats result in the lengthening of the polyglutamine stretch in the encoded protein ataxin-2. However, the normal biological function of ataxin-2 and the exact pathogenesis of expanded polyglutamine in ataxin-2 remain largely unknown (Lastres-Becker et al. 2008a) . Ataxin-2 is a widely expressed protein and may play a role in mRNA homeostasis through its interaction with ataxin-2 binding protein 1 (A2BP1/Fox-1) (Shibata et al. 2000) and may regulate plastin-associated actin filament organization and endocytosis by interacting with endorphin proteins (Ralser et al. 2005) . Ataxin-2-deficient mice are viable although Atxn2−/− mice showed reduced fertility (Lastres-Becker et al. 2008b ) and there was a significant reduction in the number of female Atxn2+/− and Atxn2−/− mice born (Kiehl et al. 2006) . They also show adult-onset obesity (Kiehl et al. 2006) , dissociated fear and spatial learning (Huynh et al. 2009 ), locomotion hyperactivity, and liver steatosis (Lastres-Becker et al. 2008b) . Transgenic mice expressing ataxin-2 with a 58-glutamine (58Q) track showed progressive functional deficits with loss of the Purkinje cell dendritic arbor and eventual loss of Purkinje cells accompanied by cytoplasmic polyglutamine-containing microaggregates, closely mimicking human SCA2. Another transgenic mouse model expressing 75Q under the regulation of the ATXN2 promoter, which has been shown to preferentially drive the expression in the cerebellum and olfactory bulb, showed specific Purkinje cell degeneration (Aguiar et al. 2006; Scoles et al. 2012) . However, such animal models still have limitations as faithful models of human neurological diseases such as SCA2 due to the interspecies difference between mice and humans. The emergence of iPS cells, which are generated by direct reprogramming of human somatic cells, offers an alternative cellular model for mechanistic study (Takahashi et al. 2007; Yu et al. 2007; Kastenberg and Odorico 2008) . Patient-derived iPS cells will preserve the genetic mutation carried by the patient on a functional human genomic background, which cannot be accomplished in animal models. Furthermore, they can be differentiated into human cells of the neural lineage, which are not readily available. In this study, we have generated a human SCA2 iPS cell line and characterized it as an in vitro disease model. 
Materials and Methods

Reagents and
Identification and Recruitment of Study Subjects
The study was approved by the University of Florida Institutional Review Board. The SCA2 subject was a 30-year-old male with 20/44 CAG repeats. A 51-year-old male with no medical problems was biopsied as a control. All human subjects were provided with the approved informed consent.
Skin Biopsy and Culture of Human Dermal Fibroblasts
Skin biopsy was performed by punch biopsy (6 mm in diameter) under local anesthesia. The skin specimens were placed in sterile DMEM culture medium supplemented with 20 % FBS and penicillin/streptomycin at room temperature for transport to the lab. Biopsy specimens were processed into 0.5 mm cubes. Fifteen pieces were placed into duplicate 25-cm 2 flasks. The explants were allowed to air-dry for 30 min, and 12 ml of primary culture medium (DMEM with 20 % FBS) was added to the flask. The flasks were placed into a 37°C, 5 % CO 2 humidified circulating incubator. Medium was removed and fresh primary culture medium was replenished after 7 days. When FBs from adjacent explants started merging, the flasks were treated with 0.05 % Trypsin/EDTA and passaged to a 75-cm 2 flask. These cells were designated as passage 1. Passage 3 FBs were used for reprogramming.
Generation of iPS Cells
Reprogramming was performed with the four traditional Yamanaka factors using retroviral vectors. Retroviruses, one for each of the four reprogramming factors (i.e., Oct4, Sox2, Klf4, and c-Myc) and enhanced green fluorescent protein (EGFP), was individually packaged using 293FT human embryonic kidney cell line (Invitrogen). After 72 h of virus production, cell supernatant was filtered through a 0.45-μM pore size filter, and the virus was concentrated by centrifugation for 16 h at 8,000×g at 4°C. Oct4, Sox2, Klf4, and c-Myc viruses were combined and used for transduction. Transduction efficiency was monitored using additional FBs retrovirally transduced with EGFP virus alone. One day prior to transduction, FBs were plated at a density of 1×10 5 cells/ 9.5 cm 2 cell culture dish in DMEM containing 15 % FBS. On day 5 after transduction, each 9.5-cm 2 plate was passaged to a 56-cm 2 dish with feeders (6.7×10 5 mitomycin-C mitotically inactivated MEFs). On day 6, the medium was changed from DMEM containing 15 % FBS to iPS cell medium. Half of the medium was removed and replaced with fresh iPS cell medium every other day (days 8, 10, 12, etc.) until colonies were ready for harvesting. Propagation and freezing of iPS cells were performed according to published protocols (Baharvand 2010; Mollamohammadi et al. 2009 ). MFreSR freezing medium (StemCell Technologies) was used to prepare iPS cell frozen stocks.
Characterization of iPS Cells
Karyotyping Karyotyping was performed by G-banding to examine the integrity of the chromosomes by the Cytogenetics Laboratory at the University of Florida.
RT-PCR of Stem Cell Markers Total RNA was extracted using RNaeasy Micro Kit (Qiagen, Valencia, CA). cDNA was synthesized using Invitrogen/Gibco kit (SuperScript III Reverse Transcriptase, No. 18080) from 1-μg total RNA in a final volume of 20 μl; 1 μl was used for subsequent PCR. Stem cell marker RT-PCRs was performed using published primers (Takahashi et al. 2007 ) targeting endogenous human OCT4, SOX2, NANOG, and MYC. hOCT 4: F 5′-GAC AGG GGG AGG GGA GGA GCT AGG-3′, R 5′-CTT CCC TCC AAC CAG TTG CCC CAA AC-3′; hSOX2: F 5′-GGG AAA TGG GAG GGG TGC AAA AGA GG-3′, R 5′-TTG CGT GAG TGT GGA TGG GAT TGG TG-3′; hNANOG: F 5′-CAG CCC TGA TTC TTC CAC CAG TCC C-3′, R 5′-GG AAG GTT CCC AGT CGG GTT CAC C-3′; hMYC: F 5′-GCG TCC TGG GAA GGG AGA TCC GGA GC-3′, R 5′-TTG AGG GGC ATC GTC GCG GGA GGC TG-3′; beta-actin was amplified as an internal control. PCR was carried out in a final volume of 20 μl containing 0.5 μM forward and reverse primers, using AmpliTaqGold 360 master mix. The initial denaturation at 95 C for 3 min was followed by 36 cycles of denaturation at 95°C for 30s, annealing 60°C (except for beta-actin 55°C) for 30s and elongation at 72°C for 1 min, and a final elongation step of 10 min at 72°C. Electrophoresis of the PCR products was carried out on 1.6 % agarose gel.
Alkaline Phosphatase Activity Assay and Immunocytofluorescence Staining of Stem Cell Markers The assays were performed on IbidiTreat μ-Slides. 3-5 iPS cell clumps (around 100 cells) were seeded into chambers with feeders and cultured for 2-3 days to allow the colonies to expand. For the alkaline phosphatase activity assay, the chamber was incubated with Liquid Fast-Red Substrate System (Thermo Scientific, TA-060-AC) overnight at 4°C. Nuclear transcription factor Oct4 and cell surface marker SSEA4 were examined by immunocytofluorescence staining. The slides were washed with PBS and fixed in 4 % paraformaldhyde for 5 min, permeabilized with 0.3 % Triton X-100 for 15 min, blocked with 10 % normal goat serum (Vector Lab) for 30 min, and incubated with Oct4 or SSEA4 (1:100) overnight at 4°C. The slides were washed and incubated with goat anti-mouse FITC-conjugated secondary antibody (1:500; StemCell Technologies) for 30 mi. Afterwards, slides were washed and mounted with Vectashield mounting medium with DAPI (Vector Laboratories, H-1200). Pictures were taken under confocal microscope (Olympus IX81-DSU Spinning Disk).
Prolonged Self-renewal iPS cells were passaged at 1:4 ratios approximately every 4-5 days and were maintained to a passage 35 at the time of this submission. Over this time, iPS cell growth pattern and morphology were recorded.
Embryoid Body Formation
Undifferentiated colonies (P 21 of SCA2 iPS cells and P 8 of normal control iPS cells) were detached with Collagenase IV (1 mg/ml) and Trypsin-EDTA (0.05 %) for 20 min; cells were flushed with 1 ml large bore tips and passed through a 70-μm cell strainer to remove single cells and MEFs. Next, the strainer was turned over to collect all the colonies by washing with DMEM/F12 medium. Colonies were centrifuged at 192×g for 3 min, resuspended in 3 ml accutase, and incubated for 25 min at 37°C, pipetting every 5 min to make a single cell suspension. Cells were passed through a 37-μm cell strainer and 7 ml of DME/F-12 medium was added, and then they were centrifuged at 300×g for 5 min.
Cell pellets were resuspended in embryoid body (EB) medium to generate 1×10 6 cells/ml, and 2 ml was added to each well of an AggreWell 800 plate (StemCell Technologies). The plate was centrifuged at 100×g for 3 min to capture the cells in the microwells. Three fourths of the medium was changed daily for 4 days. EBs were then detached by flushing the microwells with induction medium and transferred to a low attachment 6-well plate for further culture for 5 days. Some EBs were transferred to IbidiTreat μ-Slides for differentiation. EBs growing in 6-well plates were collected and embedded in agarose, fixed in 4 % paraformaldhyde overnight, and embedded in paraffin for subsequent staining.
Immunohistochemical Staining of EB Pluripotency was assayed by immunohistochemical staining of AFP (endoderm), desmin (mesoderm), and neural differentiation (ectoderm; see "Neural Differentiation" below); 4 μm sections from paraffin-embedded EBs were used for immunohistochemical staining of AFP and desmin. Sections were de-paraffinized and incubated with 3 % H 2 O 2 /methanol to block endogenous peroxidase activity, and then treated with Antigen Retrieval Citra Solution (BioGenex, HK086-9K) for 30 min. Background Sniper (Biocare Medical, l# BS966M, Walnut Creek, CA) was used to reduce nonspecific background staining. Sections were incubated with AFP (1:100) or desmin (1:100) antibody overnight at 4°C. After incubation with secondary antibody, sections were developed using diaminobenzidine chromogen (Biocare Medical, Walnut Creek, CA) and lightly counterstained with Hematoxylin (Biocare Medical, Walnut Creek, CA).
Neural Differentiation
Neural differentiation using AggreWell 800-AggreWell 800 was prepared following manufacture's protocol. Single cell suspension was prepared as described above in EB formation but with STEMdiff Induction Medium (StemCell Technologies) supplemented with ROCK inhibitor to final concentration of 10 μM; 1.2 to 2.5×10 6 cells were seeded in each well of the AggreWell 800 in a total volume of 2 ml. The plate was centrifuged at 100×g for 3 min to capture the cells in the microwells, and three fourths of the medium was changed daily for 5 days. Over this time, the iPS cells collected at the bottom of the well aggregated to form neurospheres. The spheres were flushed from the microwells using neural induction medium and were transferred to a polyornithine-laminin-coated 6-well plate (one well of the AggreWell 800 well to one well of a 6-well plate). Neurospheres attached and medium was changed daily. On day 7, neural rosettes were detached using STEMdiff Neural Rosette Selection Reagent and transferred to one well of a 6-well plate coated with poly-ornithine-laminin. Neural stem cells (NSCs) start growing out of neural rosettes in 12 h. Cells were cultured for 7 days. NSCs were detached with accutase to make a single cells suspension and transferred to a 6-well plate at a density of 1-5×10 5 per well as NSC passage 1. 4 × 10 4 /ml cells were seeded to IbidiTreat μ-Slides and cultured in Neural Induction medium for observation and staining of neural markers. For further propagation and differentiation, NSC were detached using accutase and grown either in suspension or as attached cells using NeuroCult NS-A proliferation medium.
Neural differentiation using the EB method was performed as reported (Hu and Zhang 2010) but commercial induction medium (STEMdiff Neural Induction Medium, StemCell Technologies) was used.
Immunocytofluorescence Staining of Ataxin-2 and Neural Cell Markers
These studies were performed on IbidiTreat μ-Slides. 40 μl of NSCs at density of 1X10 6 /ml were seeded to IbidiTreat μ-Slides and cultured in Neural Induction Medium for observation and staining of neural markers. Cells were cultured for 3-5 days to allow for spontaneous differentiation. The slides were then washed twice with PBS, fixed in 4 % paraformaldhyde for 5 min, washed once with PBS, permeabilized with 0.3 % Triton X-100 for 15 min, washed once with PBS, blocked with 10 % normal goat serum (Vector Lab # S-1000) for 30 min, and incubated with ataxin-2 (1:100), nestin (1:100), neurofilament H (1:50), beta-tubulin III (1:250), GFAP (1:500), or calbindin (1:250) overnight at 4°C. The following day, slides were washed three times with PBS, incubated with the appropriate secondary antibody conjugated with AF 555 or AF 488 (1:500; Invitrogen) for 30 min, washed with PBS, and mounted with Vectashield Mounting Medium with DAPI. Pictures were taken under confocal microscope (Olympus IX81-DSU Spinning Disk). For double immunocytofluorescence staining, ataxin-2 and nestin or neurofilament H antibodies were co-incubated overnight at 4°C. AF488 goat anti-rabbit and AF 555 goat anti-mouse secondary were coincubated at room temperature for 30 mi.
Western Blot
Western blot was performed as previously described (Xia et al. 2005) . Briefly, 20 μg whole cell lysate was run on 4 to 20 % Tris-glycine gradient gel. Membranes were first probed with ataxin-2 antibody (1:1,000) overnight, washed and probed with the secondary antibody and developed. The membranes were then stripped with Restore Western Blot Stripping Buffer (Pierce) and reprobed with β-actin to confirm equivalent loading and transfer of protein. Signal was detected using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce).
Time-Lapsed Study of Neural Differentiation
4X10
4 NSCs were seeded in IbidiTreat μ-Slides and cultured in STEMdiff Neural Induction Medium (StemCell Technologies). Three fields were observed every 12 h and successive photos were taken for analysis of cell survival. Only neurons were tracked and counted. The survival rates at 50 h were compared between SCA2 and control neurons.
SCA2 CAG Expansion PCR
Genomic DNA was isolated from cultured cells using Qiagen DNeasy Blood and Tissue kit (No. 69506). The region containing the SCA2 CAG repeat was PCR amplified using previously published primers: F, 5′-GGGCCCCTCACCATGTCG-3′; R, 5′-CGGGCTTGCGGACATTGG 3′ (Pulst et al. 1996) . PCR was carried out in a final volume of 20 μl, containing 100 ng genomic DNA, 0.5 μM forward and reverse primer, and AmpliTaq master mix with denaturation at 95 C for 3 min, followed by 36 cycles of denaturation at 95°C for 30 s, annealing at 56 C for 30 s, and elongation at 72 C for 1 min, and a final elongation step of 10 min at 72°C. Electrophoresis of the PCR products was carried out on a 2 % agarose gel. For repeat stability analysis, the precise sizes of the fluorescent PCR product were determined by DNA Analyzer 3720XL (Applied Biosystems).
Statistical Analysis
Time-lapsed neuronal survival study between SCA2 neurons and control neurons was compared by Fisher's exact test using IBM SPSS Statistics 20.
Results
Reprogramming Efficiency of Skin FB is Similar During SCA2 and Normal iPS Cell Generation
The growth patterns of SCA2 and normal FBs were not different ( Supplementary Fig. 1 ). Cells from passage 3 were used for iPS cell generation. The traditional retroviral method had similar transduction efficiency between SCA2 and control cells (Supplementary Fig. 2 ). Colonies with typical hESC morphology started appearing between days 17 and 19 and were ready to isolate around day 30 for both SCA2 and control iPS cells. The method yields a reprogramming efficiency of roughly 0.01 %. Four to ten individual clones were further propagated. Clone number 2 of SCA2 iPS cells, and clone number 10 of control iPS cells were used below.
Both SCA2 iPS Cells and Normal Control iPS Cell Have Pluripotent Stem Cell Features
Both SCA2 and control iPS cells grew as flat, wellcircumscribed colonies on feeder cells in iPS cell culture medium. The colonies contained tightly compacted cells with a high nucleus to cytoplasm ratio (Fig. 1, only SCA2 iPS cells are shown). The iPS cell colonies maintained similar growth rates and patterns through subsequent passages. Karyotyping and genetic analysis showed normal male karyotype (metaphase number of chromosome046) without clonal structural or numerical aberrations for SCA2 and normal iPS cells (Supplementary Fig. 3 ). Agarose gel electrophoresis of RT-PCR-amplified Oct4, Nanog, and Sox2 mRNA demonstrated that SCA2 iPS cells, but not the original FBs, expressed these stem cell markers. In contrast, c-Myc is ubiquitously expressed in both somatic and stem cells ( Supplementary  Fig. 4) . A similar expression pattern was also found in control iPS cells (data not shown). Immunocytofluorescence analysis of stem cell markers in SCA2 and control iPS cell colonies stained positive for alkaline phosphatase, Oct4, and SSEA4 while the surrounding feeder cells served as a negative control (Fig. 2) . To analyze the pluripotency, we performed EB formation assay. SCA2 EBs showed normal morphology and differentiation in culture chambers (Fig. 3a, b) . Cell differentiation was confirmed by immunohistochemical staining of AFP (for endoderm) (Fig. 3c) and desmin (for mesoderm) (Fig. 3d ) on paraffin-embedded EBs. Ectoderm differentiation was evaluated by neural differentiation. 
SCA2 iPS Cell Neural Differentiation is Deviated from Normal Process
Neural differentiation of SCA2 iPS cells was compared with control iPS cells. Both SCA2 and control iPS cells aggregated and formed neurospheres in the microwells (Fig. 4a,  e) . Control iPS cells had subsequent normal neural differentiation. Neural rosettes started forming 3 days after neurospheres attachment (Fig. 4b) . NSCs egressed from attached neural rosettes and re-grouped into small, loosely arranged rosettes (Fig. 4c, d ) from which spontaneous differentiation occurred (Fig. 4d, white arrow) . However, neural rosette formation from SCA2 iPS cells was abnormal after transfer to poly-ornithine-laminin-coated plates, as compared with rosettes from control iPS cells. Instead of forming neural rosettes, SCA2 neurospheres evolved into a cyst-like structure with a pedicle from which NSCs (white arrow) emerged (Fig. 4f ). SCA2 NSCs also had a tendency to spontaneously differentiate at early passages. Neural differentiation using the EB method yielded similar differences. SCA2 NSCs expressed GFAP and nestin (Fig. 5a, b ) and could further differentiate into neurons and astrocytes (Fig. 5c-e) . Some of these neurons expressed calbindin (Fig. 5f ). During subsequent passages, NCSs cultured in suspension were able to form spheres. Once these spheres were seeded onto poly-ornithine-laminin-coated plates, they attached and grew out of the sphere in a bipolar shape (Fig. 5g, h ). However, when NSCs grew to confluence, they tended to form spheres again (Fig. 5i) . Similar findings were seen in control NSCs (data not shown). These NSCs (the latest passage of P7) maintained their potential of further neural differentiation and formed a neural network (Fig. 6a, b) . 
SCA2 NSCs Express Less Ataxin-2 Compared with Normal NSCs
Western blot analysis was performed to compare the expression of ataxin-2 between neural lineage cells (NSCs) and non-neural lineage cells (FBs) derived from SCA2 and control iPS cells. Specific bands around 150 kD (predicted size for ataxin-2) were detected. We found SCA2 NSCs expressed less ataxin-2 than normal NSCs and SCA2 FBs. In SCA2, NSCs in both mutant and wild-type protein appear to be equally expressed (Fig. 7) . The differential expression of ataxin-2 in subtype of neural lineages cells was compared by immunofluorescence (IF) staining below.
Neuron Cells Express More Ataxin-2 Than Glia
Newly generated NSCs had the tendency to spontaneously differentiate, which resulted in coexistence of NSCs, neurons, and glia in culture. Ataxin-2 expression in neural lineage cells was examined by double IF staining of ataxin-2 and specific neural markers. We found ataxin-2 was expressed most abundantly in newly differentiated neurons. Nestin and Neu Hnegative cells (glia-like) had the least expression. No cytoplasmic or nuclear inclusion was detected (Fig. 8) .
SCA2 Neural Cells Have Shorter Life Span Compared with Normal Control Neural Cells
Neuronal growth in culture was compared by time-lapse imaging. Imaging of the same group of neurons over successive days showed that the mean survival rate for SCA2 neurons (total 21 cells) was shorter compared with normal control neuronal cells (total 64 cells; 33.3±17 vs. 100±0 %, p00.00) within 50 h after differentiation calculated from three different fields (Fig. 9) .
CAG Repeats Remained Stable During Reprogramming and Neural Differentiation
Expansion of the CAG repeats in ataxin-2 gene was verified by genomic PCR and sequencing in FBs and the established SCA2 iPS clone. The normal allele had two CAA interruptions in the (CAG) 8 CAA(CAG) 4 CAA(CAG) 8 configuration, while the expanded allele had pure (CAG) 44 without interruption. The expanded allele showed no detectable differences in blood, FB and iPS cells (Supplementary Fig. 5a ). Serial passage of SCA2 FBs (P0-P19; Supplementary Fig. 5b ), iPS cells (P9 and P26; Supplementary Fig. 5c ), and NSCs (P2; Supplementary Fig. 5c ) all showed stable CAG repeats. The CAG expansion in the ATXN2 gene was further stably . NSCs egressed from re-plated neural rosettes and still maintained the tendency to form small loosely arranged rosettes (c-d), from which spontaneous differentiation occurred (d arrow). In contrast, neural rosettes never formed during SCA2 iPS cell neural differentiation. After attaching to poly-ornithine-laminincoated plates, SCA2 neurospheres (e) formed a cyst-like structure with a pedicle, from which NSCs (arrow) egressed (f) maintained throughout the reprogramming and neural differentiation processes (Supplementary Fig. 5c ). All repeat sizes were further confirmed by PCR with fluorescent-labeled primer and capillary electrophoresis.
Discussion
The main result of the present study was the successful generation of a line of mutant iPS cells from an SCA2 subject and the identification of a neuronal defect in SCA2 during neural development. To date, the SCA2 iPS cells have been propagated to passage 37 with stably expanded CAG repeat size and growth morphology. We have also demonstrated in vitro pluripotency, self-renewability, and neural differentiation of these cells. Furthermore, NSCs (neural progenitor cells) derived from the SCA2 iPS cell line underwent multiple passages without losing neural differentiation capability. Thus, the SCA2 iPS cells can serve as an unlimited resource for an ideal in vitro cellular model for SCA2. Since the first reprogramming of human somatic cell to iPS cell using retroviral vectors (Takahashi et al. 2007 ), many integration-free methods have been developed Fig. 5 SCA2 NSCs expressed GFAP (a) and nestin (b) and further differentiated into neurons and astrocytes (c, d double staining with neurofilament H (red) and GFAP (green); e beta-tubulin III). Some of the neurons expressed calbindin (f). During subsequent passage, NSCs cultured in suspension formed spheres. When these spheres were seeded to poly-ornithinelaminin-coated plates, they attached and NSCs grew out of the sphere in a bipolar shape (g, h). However, when NSCs grew to confluence, they tended to form spheres again (i). Similar finding were observed in control NSCs (data not shown) Fig. 6 Passage 7 of control NSCs (a) and SCA2 NSCs (b) still maintained the potential for further neural differentiation and formed a neural network (36 h after neural differentiation) Fig. 7 Western blot of ataxin-2 expression in normal and SCA2 cells. SCA2 NSC showed less ataxin-2 expression compared with normal NSCs. SCA2 NSCs had lower expression compared with SCA2 FBs to enhance the safety in future clinical cell-based therapy Yu et al. 2009; Warren et al. 2010 ). There are also successful reports of reprogramming using different combinations of core transcription factors (Yu et al. 2007; Huangfu et al. 2008; Nakagawa et al. 2008) . However, reprogramming with the four traditional Yamanaka factors using retroviral vectors remains the optimal method for high reprogramming efficiency. As our primary purpose for this study was to establish a cellular model for the study of pathogenesis and drug screening, we justified the use of Yamanaka's method although our iPS cells are not suitable to clinical cell-based therapy.
SCA2 is caused by an expansion of polyglutaminecoding CAG repeat in the ATAXN2 gene. This mutation produces the ataxin-2 protein containing an elongated polyglutamine tract. Normal individuals have 13 to 31 CAG repeats whereas individuals with SCA2 have 32 to 79 repeats, with some in the range greater than 200 repeats (Pulst et al. 1996; Babovic-Vuksanovic et al. 1998) . Lateonset, L-DOPA-responsive Parkinson's disease, either in isolation or association with the SCA2 phenotype, has been found in patients with 32 to 39 SCA2 CAG repeats. Recent studies have shown 29 or more CAG repeats are associated with ALS, designated ALS13 (OMIM No. 183090) (Elden et al. 2010) , and the small full-expansion SCA2 allele may cause ALS phenotype (Van Damme et al. 2011) . The pathogenic mechanism of SCA2 has been attributed to polyglutamine toxicity rather than loss of ataxin-2 function as Atxn2 knockout mice have normal neural development (Kiehl et al. 2006 ). In the current study, we found SCA2 NSCs express less ataxin-2 when compared with normal control NSCs. Although additional studies are needed to confirm these findings, the reduced ataxin-2 expression level in SCA2 NSCs may be relevant to the pathophysiological mechanism of SCA2. The ATXN2 promoter is located in a typical CpG island in exon 1 of the ATXN2 gene and is usually partially methylated. Using a methyl-specific PCR (Laffita-Mesa et al. 2012), Laffita-Mesa et al. found that alleles with pathogenic CAG expansions were preferentially hypermethylated and hypermethylation at the promoter lead to partial or complete epigenetic silencing. They also noted that Fig. 9 Time-lapse imaging of neurons over successive days. Within 50 h, all control neurons were viable (top, low right-hand-corner numbers are change of neuron number over time). In contrast, SCA2 neurons were short-lived (bottom) hypermethylation was associated with longer expansions of the ATXN2 repeat. While these findings may represent part of the cellular defense mechanism to reduce the burden of cytotoxic mutant ATXN2, ataxin-2 deficiency has been implicated to be detrimental during the embryonic development (Kiehl et al. 2006; Lastres-Becker et al. 2008b ). The decreased expression of ATXN2 in our SCA2 NSCs suggests that cells at early differentiation stages may be particularly susceptible to hypermethylation. In a recent infant SCA2 patient with 92 CAG repeats presented with facial dysmorphism, dystonia, developmental delay, and retinitis pigmentosa (Di Fabio et al. 2012) , the developmental phenotype may be relevant to the gene silencing mechanism. However, we found differentiated neurons had a higher expression level of ataxin-2, which may explain why neurons are more susceptible to degeneration based on polyglutamine toxicity. Thus, we propose that both decreased expression of ATXN2 and polyglutamine toxicity play roles in SCA2 pathogenesis. Ataxin-2 loss of function may cause early depletion of NSCs while polyglutamine gain of function may contribute to degenerative neuron loss at later ages.
The main pathological characteristics of SCA2 in the brain are cytoplasmic polyglutamine inclusion bodies and PC loss with poor dendritic arborization and torpedo-like axons, which are accompanied by neuronal losses in the pontocerebellar nucleus, inferior olive, substantia nigra, and in some cases, thalamus and reticulotegmental nucleus of pons (Geschwind et al. 1997; Huynh et al. 2000; LastresBecker et al. 2008a) . Reduced size and number of spinal motor neurons and Clarke's column and demyelination of dorsal roots and dorsal columns have also been reported. The cytoplasmic location of polyglutamine aggregates on histopathology, a combination of cerebellar ataxia, loss of ocular saccades and areflexia on clinical phenotype, and associations with Parkinson's disease and ALS distinguish SCA2 from other SCAs (Lastres-Becker et al. 2008a ). Interestingly, ataxin-2, a cytoplasmic RNA binding protein and constituent protein of stress granules, is a potent modifier of the toxicity of TDP-43, which is one of the key molecules in ALS and other neurodegenerative disorders (Ito and Suzuki 2011) . Furthermore, ataxin-2 is a key "hub" protein in the ataxia interactome, a molecular network involved in the pathogenic mechanism of degenerative ataxias (Lim et al. 2006) . While the neuronal cell culture model derived from SCA2 iPS cells will not be able to address tissue specificity of the SCA2 pathology until technological advances allow us to differentiate iPS cells into specific types of neurons, they will be useful for providing fundamental cellular pathophysiology involved in SCA2 and, potentially, in Parkinson's disease, ALS and other degenerative ataxias.
Little is known when the mutant protein with elongated polyglutamines starts to accumulate and how it is chronologically related with neuronal loss in SCA2. We did not find cytoplasmic or intranuclear inclusions in NSCs or newly differentiated neural cells. The study of neural tissues in the teratoma derived from SCA2 iPS cells may provide further insight into understanding the timing of polyglutamine micro-aggregation during neuronal differentiation. Existing evidence from animal studies suggests that the neurological phenotype may emerge prior to neuronal loss in polyglutamine expansion disorders (Clark et al. 1997; Lorenzetti et al. 2000; Chen et al. 2008; Liu et al. 2009; Shakkottai et al. 2011 ). Thus, both neuronal dysfunction and neuronal loss are likely to play roles in phenotypic expression in these disorders. The neuronal cells derived from our SCA2 iPS cells appeared to have a shorter life span in culture compared with those derived from control iPS cells. Further studies of cell death mechanisms and electrophysiological properties of ion channels in SCA2 iPS cells will provide insights into the pathophysiology behind the neuronal dysfunction leading to development of the clinical phenotype of ataxia.
In polyglutamine expansion disorders, expanded alleles are prone to change in repeat length (Jodice et al. 1997 ). This happens during both meiosis and mitosis (Chong et al. 1995) . In SCA2, most normal alleles are interrupted by CAA trinucleotides but the expanded alleles have longer than 35 pure CAG units (Imbert et al. 1996) . In our SCA2 iPS cells, both the expanded allele and normal allele remained stable in size during reprogramming, proliferation and differentiation from stem cells to terminally differentiated neurons. There has been only one research paper addressed the trinucleotide repeat stability during reprogramming. Ku et al. described GAA triplet repeats in the FXN gene showed both expansions and contractions in iPS cells from two patients with Friedreich's ataxia (Liu et al. 2011) . Since the degree of repeat instability is known to depend on the length of the pure repeat tract, the sequence of the repeat unit, and the cellular environment (Wells and Ashizawa 2006) , the remarkable stability of the expanded allele in our cells is not surprising. However, we expect the expanded SCA2 allele will show some degree of instability in further somatic and germline differentiation of our iPS cells, especially if sensitive assays, such as small-pool PCR (Monckton et al. 1995) are employed. The relative stability of the CAG expansion size during the establishment and subsequent neuronal differentiation of our SCA2 iPS cells assures the consistency and integrity of these cells as a cellular model.
Effective disease modeling with human iPS cells has been demonstrated in neurodegenerative and neurodevelopmental disorders, such as spinal muscular atrophy (Ebert et al. 2009 ), familial dysautonomia (Lee et al. 2009) , and familial Parkinson's disease (Soldner et al. 2009; Hargus et al. 2010; Seibler et al. 2011) . In these studies, iPS cells recapitulated some disease features and showed potential to become a platform for drug development (Ebert et al. 2009; Lee and Studer 2011) . Successful generation of iPS cells has also been reported in ataxic disorders, such as Friedreich's ataxia and ataxia telangiectasia (Ku et al. 2010; Kinoshita et al. 2011) . At the writing of this manuscript, SCA7 iPS cells have been reported and demonstrated the capability for neural differentiation (Luo et al. 2012) . In addition to the current SCA2 iPS cells, iPS cell repositories for SCAs (SCA1, SCA3, SCA5, SCA6, SCA8, SCA10, and SCA13) are all in line for generation in our center. These disease-specific iPS cells are promising in future studies for: (1) further differentiation to specific types of neurons and glia including those in the cerebellum, (2) the pathogenic mechanism of SCAs, (3) the development and screening of therapeutic drugs, (4) correcting expansion mutations to normal repeats, and (5) cell engrafting studies in mutant mouse models to gain knowledge for future cell-based therapy.
